Citi raised the firm’s price target on Blueprint Medicines to $65 from $54 and keeps a Sell rating on the shares. In Q4, Ayvakit beat estimates, but the current rate of quarter-over-quarter patient adds and fiscal 2024 Ayvakit guidance hints at potentially moderating trajectory towards the end of 2024 and beyond, the analyst tells investors in a research note. The firm expects peak sales will fall short of Blueprint’s $2B projection.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BPMC:
- Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
- Blueprint Medicines price target raised to $70 from $58 at Barclays
- BPMC Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Blueprint Medicines price target raised to $90 from $85 at Oppenheimer
- Blueprint Medicines price target raised to $78 from $58 at Piper Sandler
